Semaglutide and Tirzepatide are once-weekly injectable medications originally developed for type 2 diabetes. They mimic GLP-1, a natural hormone that regulates appetite and blood sugar. By slowing gastric emptying and promoting satiety, they help reduce food intake and support sustained weight loss. Tirzepatide also includes GIP, offering enhanced metabolic benefits.
These treatments are for educational purposes only and are not intended to diagnose, treat, cure, or prevent any disease. Peptide, exosome, and PDGF therapies may be used off-label and are provided under physician supervision only.Support sustainable weight loss, reduce appetite, improve blood sugar, and enhance metabolic health.
Systemic treatment—targets overall body fat, especially stubborn areas like abdomen, thighs, and arms.
Semaglutide / Tirzepatide (GLP-1)
Controls appetite, improves metabolism, and supports safe, effective weight loss.
Pre-Treatment
No specific preparation required; follow dosage instructions and maintain a balanced, low-glycemic diet.
Post-Treatment
Monitor for mild nausea or appetite changes; stay hydrated and follow your prescribed dosing schedule.
What to Expect
You may feel reduced appetite and mild nausea. Most resume normal activities right away.
Steady weight loss, reduced appetite, improved blood sugar control, and better metabolic health over time.
Injections are typically given weekly; follow your provider’s plan for dose adjustments and monitoring.
Not recommended during pregnancy due to effects on metabolism and appetite regulation.
Mild discomfort at injection site; most patients find it very tolerable.
